We are live on ! Find out more
IONS icon

Ionis Pharmaceuticals
IONS

54.93 USD
-1.82
3.21%
At close Updated Jul 14, 4:00 PM EDT
Pre-market
After hours
55.20
+0.27
0.49%
1 day
-3.21%
5 days
-35.8%
1 month
-25.73%
3 months
-28.44%
6 months
-30.35%
Year to date
-31.05%
1 year
29.1%
5 years
55.79%
10 years
124.02%
 

About: Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).

Employees: 1,402

Healthcare Biotechnology
0
Funds holding %
of 8,119 funds
Explore Fund Trends
0
Positive news %
of 26 articles
Check Journalist POV
Price charts implemented using Lightweight Charts™